Revista de bioprocesamiento y biotecnologías

The Expression of VEGFR2 and VEGFR3 in Early Gastric Cancer and Its Clinical Significance

Abstract

Xiu-Feng Li*, Yun-Xiang Zhang, Ting-Guo Zhang and Min Yang

Background: To explore the expression and its clinical significance of vascular endothelial growth factor receptor II and III (VEGFR2 and VEGFR3) in early gastric cancer.
Methods: Immunohistochemical method is applied to detect 120 cases of early gastric cancer and normal gastric tissue of its cut edge in the expression of VEGFR2 and VEGFR3.
Results: The positive expression rates of VEGFR2 and VEGFR3 in early gastric cancer are 75% and 60%, which are higher than in normal gastric tissues of cut edge (22.5%, 12.5%), respectively. The expression of VEGFR2 and VEGFR3 is associated with depth of invasion, lymph node metastasis (P<0.05), regardless of patient's gender, age, tumor size, gross classification, differentiation (P>0.05).
Conclusion: VEGFR2 and VEGFR3 play important roles in occurrence and development of early gastric cancer, which potentially provides a basis for targeted molecular therapy of early gastric cancer.